Videos | Bringing pharma’s top innovators to your screen

Oncology

ASCO 2026: Powerful evidence for the microbiome in oncology,...

Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Oncology

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Oncology

ASCO 26: Precision medicine takes a village, with Carolyn So...

In this interview with pharmaphorum, J&J's Henar Hevia and Carolyn Sousa, share their some of the company's data wins at the show and talk trends.

Oncology

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.

Oncology

Interview at ASCO 26 with David Spetzler

ASCO26: AI supercharging gene-based cancer detection, with D...

Pharmaphorum caught up with Caris Life Science's David Spetzler to talk about how agentic AI is empowering whole genome sequencing in cancer detection

Sales & Marketing

Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Sales & Marketing

Interview at JPM26 with Helen Sabzevari and Greg Skalicky

Rewiring commercialisation to meet the moment, with Helen Sa...

At the Informa Biotech Showcase at JPM2026, EVERSANA President Greg Skalicky and Helen Sabzevari, CEO of Precigen, discuss new commercialisation.

Digital

Interview at Reuters Pharma EU with Florian Schnappauf, Veeva

From data to deployment: Navigating AI adoption in pharma wi...

Explore our video interview for expert tips on AI adoption in pharma, featuring Veeva.

Digital

Inizio Ignite, STEM AI video feature image

STEM AI: Delivering intelligent data-led HCP interactions

In a new sponsored video, pharmaphorum spoke with experts from STEM, an Inizio Ignite company, about STEM AI

Market Access

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

Market Access

Interview with Marjorie Sidhoum at BIO Europe 2026

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Oncology

ASCO 2026: Powerful evidence for the microbiome in oncology,...

Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Oncology